Month: October 2018

Lexington Provides Q3 Corporate Review

VANCOUVER, British Columbia, Oct. 23, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review activities undertaken during Q3 of 2018. Over the summer, the Company completed its first phase of clinical testing at Diablo Clinical Research. The results of the study validated

Read More



Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News